Combined prognostic association between GLIM-diagnosed malnutrition and quality of life with survival in digestive cancer patients
Supportive Care in Cancer · 2026-12 · 34 (12)
DOI: 10.1007/s00520-026-11445-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 18.11.2026. Verfasst von Josune Martín und 7 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Osasun Saila, Eusko Jaurlaritzako, Red de Investigación en Servicios de Salud en Enfermedades Crónicas.
Themen: Onkologische Pflege, Mangelernährung
Abstract (Originalsprache)
Purpose
The aim of this study was to investigate the relationship between malnutrition, diagnosed using GLIM criteria, and SF-36 General Health score among patients with colorectal (CRC) and other digestive cancers and to evaluate the combined prognostic association of malnutrition and QoL with survival at 90 days and 1 year after discharge.
Methods
In a prospective cohort of 519 cancer patients, nutritional status was assessed using MUST and GLIM criteria. QoL was measured with the SF-36 and EuroQol questionnaires, and functional status with the Barthel Index. Survival was estimated using the Kaplan–Meier method, and Cox regression identified prognostic factors.
Results
Patients were 62% male with a mean age of 67.9 years; 23.51% were moderately and 21.97% severely malnourished. The most prevalent diagnosis was CRC (65.5%). Patients had moderate functional status and QoL scores at admission. Mortality was 12.5% at 90 days and 27% at 1 year. Combined low SF-36 General Health score and malnutrition was associated with 90-day mortality (HR = 6.03, p < 0.001), followed by low SF-36 General Health score without malnutrition (HR = 3.4, p < 0.05). Longer hospital stay and medical complications were associated with increased mortality, while surgery was associated with lower mortality (HR = 0.38, 95% CI 0.19–0.76, p < 0.001). At 1 year, age, CCI, stage IV cancer, and complications remained key mortality-associated factors. The impact of SF-36 General Health score was weaker than at 90 days but combined poor SF-36 General Health score and malnutrition remained significant. Models showed strong discrimination ( C -Index > 0.80).
Conclusions
Combined assessment of GLIM-defined malnutrition and self-reported general health may help identify hospitalised patients with digestive cancer who are at increased risk of post-discharge mortality. Implications for cancer survivors Whether interventions based on this risk stratification improve outcomes requires prospective interventional evaluation.
Trial registration
ClinicalTrials.gov as ID NCT04188990. Registration date: 2 December 2019.
Förderung
- Instituto de Salud Carlos III
- Osasun Saila, Eusko Jaurlaritzako
- Red de Investigación en Servicios de Salud en Enfermedades Crónicas
- RICAPPS
- Universidad del País Vasco
Zitieren
APA
Martín, J., Larrea, N., Galán-Arcicollar, C., García, Y., Bolinaga, I., Perales, A., Sarasqueta, C., & Quintana, J. M. (2026). Combined prognostic association between GLIM-diagnosed malnutrition and quality of life with survival in digestive cancer patients. Supportive Care in Cancer, 34(12). https://doi.org/10.1007/s00520-026-11445-9
Vancouver
Martín J, Larrea N, Galán-Arcicollar C, García Y, Bolinaga I, Perales A, et al. Combined prognostic association between GLIM-diagnosed malnutrition and quality of life with survival in digestive cancer patients. Supportive Care in Cancer. 2026;34(12). doi:10.1007/s00520-026-11445-9
BibTeX
@article{Martn2026,
author = {Martín, Josune and Larrea, Nere and Galán-Arcicollar, Cristina and García, Yolanda and Bolinaga, Inmaculada and Perales, Amaia and Sarasqueta, Cristina and Quintana, José M.},
title = {Combined prognostic association between GLIM-diagnosed malnutrition and quality of life with survival in digestive cancer patients},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {12},
doi = {10.1007/s00520-026-11445-9}
}
EUVIMED